Severity
Low
FDA Drug recall · Reported June 26, 2019
Labeling: Label mix-up: Product secondary carton erroneously states 40mg instead of 30 mg, primary carton is label correctly.
Akorn Inc recalled Myorisan (isotretinoin capsules, USP), 40 mg, packaged in cartons of 30 Capsules containi… - a low-severity action.
Myorisan (isotretinoin capsules, USP), 40 mg, packaged in cartons of 30 Capsules containi… was recalled by Akorn Inc in June 26, 2019. Reason: Labeling: Label mix-up: Product secondary carton erroneously states 40mg instead of 30 mg, primary carton is …. Check the official notice for the remedy. Verify recall #D-1392-2019 with the FDA Drug before acting.
The recall
Akorn Inc issued this low-severity FDA Drug recall-Labeling: Label mix-up: Product secondary carton erroneously states 40mg instead of 30 mg, primary carton is ….
Sourced from official FDA Drug enforcement records. Verify recall #D-1392-2019 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-1392-2019) was formally reported on June 26, 2019, with the manufacturer initiating the action on June 7, 2019. It is classified under Low severity (Class III), with a current status of Terminated. Akorn Inc is listed as the recalling firm, operating out of Lake Forest, IL. Federal records list the affected scope as 16,216 cartons.
The documented reason for this recall is: Labeling: Label mix-up: Product secondary carton erroneously states 40mg instead of 30 mg, primary carton is label correctly. Distribution data in the federal record shows the product reached: Nationwide USA. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
16,216 cartons
Related Recalls
6
5 from same agency
Myorisan (isotretinoin capsules, USP), 40 mg, packaged in cartons of 30 Capsules containing 3 x 10 Prescription Packs, Rx Only, Distributed by: VersaPharm Inc. - An Akorn Company, Lake Forest, IL 60045, NDC 61748-304-13
Labeling: Label mix-up: Product secondary carton erroneously states 40mg instead of 30 mg, primary carton is label correctly.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Terminated |
| Recall number | D-1392-2019 |
| Date reported | June 26, 2019 |
| Date initiated | June 7, 2019 |
| Recalling firm | Akorn Inc |
| Firm location | Lake Forest, IL |
| Affected scope | 16,216 cartons |
| Distribution | Nationwide USA |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported June 26, 2019. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.